98 related articles for article (PubMed ID: 22407029)
1. P53 and the proteasome regulate androgen receptor activity.
Guseva NV; Rokhlin OW; Glover RA; Cohen MB
Cancer Biol Ther; 2012 May; 13(7):553-8. PubMed ID: 22407029
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Frezza M; Yang H; Dou QP
J Cell Physiol; 2011 Nov; 226(11):2731-9. PubMed ID: 21448923
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells.
Harada N; Inoue K; Yamaji R; Nakano Y; Inui H
Cancer Sci; 2012 Jun; 103(6):1022-7. PubMed ID: 22360658
[TBL] [Abstract][Full Text] [Related]
4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
5. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
7. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
8. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
9. The antiandrogenic effect of finasteride against a mutant androgen receptor.
Wu Y; Chhipa RR; Zhang H; Ip C
Cancer Biol Ther; 2011 May; 11(10):902-9. PubMed ID: 21386657
[TBL] [Abstract][Full Text] [Related]
10. [Expression and regulation of androgen receptor in the androgen-independent conversion of prostate cancer cells].
Wang HF; Liu WJ; Jin J; Zhou LQ; Liang LL; Wang Y; Guo YL
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):490-5. PubMed ID: 21844951
[TBL] [Abstract][Full Text] [Related]
11. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
12. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer.
Rokhlin OW; Scheinker VS; Taghiyev AF; Bumcrot D; Glover RA; Cohen MB
Cancer Biol Ther; 2008 Aug; 7(8):1288-96. PubMed ID: 18497571
[TBL] [Abstract][Full Text] [Related]
14. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
15. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
[TBL] [Abstract][Full Text] [Related]
16. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
18. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
19. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
